Polyrizon (NASDAQ:PLRZ) announced the successful preliminary safety study of a formulation of its PL-14 Allergy Blocker, advancing the product’s development path. According to Polyrizon, the study, designed to assess...
Polyrizon (NASDAQ:PLRZ) has announced the filing of a patent application for its advanced intranasal drug delivery system Trap & Target (T&T) technology, with the Israel Patent Office (ILPO). The company stated...